Eli Lilly’s Mounjaro shows heart health benefits in head-to-head trial with older diabetes drug Trulicity
-
最新报道：Eli Lilly's diabetes drug Mounjaro demonstrated comparable cardiovascular benefits to rival Trulicity in a late-stage trial, potentially strengthening its case for broader insurance coverage. The study showed Mounjaro was similarly effective at reducing heart risks in type 2 diabetes patients with existing cardiovascular disease. This comes as Lilly seeks to expand Mounjaro's market beyond diabetes treatment following its FDA approval for weight loss last year. Analysts note these heart health findings could help Mounjaro compete more effectively against Novo Nordisk's popular Ozempic and Wegovy drugs in the lucrative GLP-1 market.
下一篇
Talktu Wins $10,000 at Pitch2Win5, Outshines 12 Finalists
- Talktu emerged victorious at the Pitch2Win5 competition, securing a $10,000 prize after ou...
24小时热点
热点专题
407106